In this context, it has been reported that treatment with bevacizumab, a humanized monoclonal antibody against VEGF, decreased the serum VEGF levels and arthritis index (Wang, Da, Li, & Zheng, 2013). The gene discussed is VEGFA; the disease is arthritic joint disease.